Should I get a PSA test?

There is no single correct answer for all men. PSA testing can detect prostate cancer early, but it also carries a real risk of overdiagnosis — detecting slow-growing cancers that would never have caused symptoms or death, leading to unnecessary treatment with lasting side effects. Australian guidelines recommend informed decision-making: men aged 50–69 should discuss the benefits and limitations of PSA testing with their GP before deciding. Men with a first-degree family history of prostate cancer or African ancestry should consider starting that conversation from age 40–45.

What is a normal PSA level?

PSA is measured in nanograms per millilitre (ng/mL). A result below 4 ng/mL is traditionally considered normal, but this threshold has important limitations — some prostate cancers produce normal PSA, and many men with elevated PSA do not have cancer. Age-adjusted reference ranges and changes in PSA over time (PSA velocity) give more information than a single number.

What happens if my PSA is elevated?

An elevated PSA result does not mean you have prostate cancer. Common non-cancer causes include benign prostatic hyperplasia (BPH), prostatitis, recent ejaculation, vigorous exercise, and recent catheterisation. Your doctor will review the result in context — your age, symptoms, PSA trajectory, and digital rectal examination — before recommending any further steps such as a repeat test, MRI, or urology referral.

Does Australia have a national prostate cancer screening program?

No. Unlike the National Bowel Cancer Screening Program, Australia does not have a population-based prostate cancer screening program. The Cancer Council Australia and the RACGP recommend against routine universal PSA screening, but support informed, individualised decision-making between men and their GPs — particularly for men aged 50–69. The key is that men understand the trade-offs before testing.

Prostate Cancer Screening and PSA Testing

What Is PSA Testing?

Prostate-Specific Antigen (PSA) is a protein produced by prostate cells. Small quantities enter the bloodstream and can be measured with a simple blood test. PSA levels rise when the prostate is enlarged, inflamed, or cancerous — but PSA is not a cancer test. It is a marker of prostate activity, and many things cause it to rise.

PSA testing is simple, inexpensive, and widely accessible in Australia via GP referral. But whether a given man should test, and what to do with the result, requires careful consideration of the evidence — and of personal values.

Why PSA Testing Is Complicated

Unlike bowel cancer screening (iFOBT) or cervical screening (HPV test), PSA testing has a genuinely contested evidence base. The debate turns on two specific problems: overdiagnosis and overtreatment.

The benefit: PSA testing can detect prostate cancer before it causes symptoms. For men with fast-growing, aggressive cancer, early detection and treatment can save lives.

The problem: The prostate commonly develops slow-growing cancers that would never cause symptoms or death within a man’s expected lifespan. Biopsy and pathology cannot always reliably distinguish these indolent cancers from aggressive ones at the time of diagnosis. Many men identified through PSA screening are treated for cancers they would have died with, not from.

The consequence: Prostate cancer treatment — whether radical prostatectomy or radiation — carries real risks of permanent urinary incontinence and erectile dysfunction. A man treated for an indolent cancer that would never have harmed him has experienced real harm with no benefit. This is the central ethical problem of prostate cancer screening.

This is why major guidelines worldwide have moved away from universal population screening toward informed, individualised decision-making.

What PSA Can and Cannot Tell You

PSA rises for many non-cancer reasons

PSA is elevated by:

Benign prostatic hyperplasia (BPH) — very common, affects more than half of men over 60
Prostatitis — inflammation or infection of the prostate
Recent ejaculation — allow 48 hours before testing
Vigorous exercise, especially cycling — allow 48–72 hours
Digital rectal examination (DRE) — avoid performing just before the blood draw
Urinary tract infection
Urinary catheter or recent cystoscopy

PSA does not detect all prostate cancers

Around 15% of men with prostate cancer have a PSA below 4 ng/mL. High-grade, aggressive cancers sometimes produce less PSA than lower-grade tumours. A “normal” PSA does not exclude prostate cancer in a symptomatic man.

A single reading is less informative than the trend

PSA velocity — the rate of change over time — is more informative than any single reading. A PSA that rises from 1.5 to 3.5 ng/mL over two years is more concerning than a stable PSA of 4.5 ng/mL. Regular monitoring over time, once a man and his doctor decide to test, provides more useful information than a one-off check.

Understanding Your PSA Result

PSA Level (ng/mL)	Approximate interpretation
< 2.5	Low risk (reassuring, especially under 60)
2.5–4.0	Intermediate; context and PSA velocity matter
4.0–10.0	Elevated; approximately 25% probability of prostate cancer on biopsy
> 10.0	Significantly elevated; approximately 50% probability of prostate cancer

These probabilities vary considerably with age, prostate size, ethnicity, and family history. The table provides approximate guidance only — the decision about next steps belongs with your doctor, who can interpret the result in full context.

What happens after an elevated result

An elevated PSA typically triggers further assessment, not immediate biopsy. Your GP or urologist may:

Repeat the PSA after 6–8 weeks, avoiding factors that artificially raise it
Order a multiparametric prostate MRI (mpMRI) — now the standard first step before biopsy in many centres; identifies suspicious areas and guides biopsy, reducing unnecessary sampling of low-risk tissue
Perform or review a digital rectal examination (DRE) — detects hardness, asymmetry, or nodules alongside the PSA
Consider PSA density (PSA adjusted for prostate volume on MRI) — a more specific marker than PSA alone
Refer to a urologist if results remain concerning or if MRI shows a suspicious lesion

PSA Thresholds and Age

The traditional threshold of 4 ng/mL was derived from older studies and has important limitations. Younger men typically have lower PSA; a level of 2.5 ng/mL may warrant further assessment in a 45-year-old. Older men often have higher PSA due to BPH; slightly elevated results require age-appropriate interpretation.

Age-adjusted reference ranges used in some Australian laboratories:

Age range	Upper reference limit
40–49 years	2.5 ng/mL
50–59 years	3.5 ng/mL
60–69 years	4.5 ng/mL
70 years and over	6.5 ng/mL

These are guidelines, not hard cutoffs. Clinical context always takes precedence.

Who Should Consider PSA Testing?

Australian guideline position

The Cancer Council Australia and the Royal Australian College of General Practitioners (RACGP) do not recommend routine universal PSA screening — but they support informed, shared decision-making for men who wish to be tested.

Current Australian guidance:

Men aged 50–69 should be offered the opportunity to discuss PSA testing with their GP — with clear information about benefits and limitations
Men with a first-degree relative (father or brother) diagnosed with prostate cancer under age 65 should consider starting this discussion from age 40–45
Men with multiple family members with prostate cancer, a known BRCA2 gene mutation, or African ancestry (higher background risk) should also consider earlier discussion

Symptoms that always warrant assessment, regardless of screening preference

Difficulty initiating urination, weak or intermittent stream
Frequent need to urinate overnight (nocturia)
Blood in urine or semen
Bone pain, particularly lower back, hips, or pelvis
Unexplained weight loss

These symptoms require clinical evaluation regardless of a man’s stance on PSA screening.

Shared Decision-Making: What to Discuss With Your GP

A good PSA conversation with your GP should cover:

What is my background risk of prostate cancer based on age, family history, and ethnicity?
If my PSA is elevated, what would the investigation pathway look like?
What are the realistic risks of prostate biopsy (infection, bleeding, pain)?
If cancer is found at an early stage, will it always need treatment — or could active surveillance be appropriate?
What are the likely outcomes and side effects of treatment?
What happens if I choose not to test, and what monitoring would be appropriate if I decline?

There is no universally correct answer. Some men place great weight on detecting any cancer early; others, knowing the overdiagnosis data, place greater weight on avoiding the risk of unnecessary treatment. Both positions are reasonable.

Active Surveillance: When Early Prostate Cancer Doesn’t Need Treatment

For men diagnosed with low-grade, low-volume prostate cancer (Gleason grade group 1, organ-confined), active surveillance — regular monitoring without immediate treatment — is now the standard recommended approach in most Australian and international guidelines.

Active surveillance typically involves:

PSA testing every 3–6 months
Repeat mpMRI at defined intervals
Repeat biopsy (often targeted by MRI findings) every 1–3 years
Transition to treatment only if there is evidence of disease reclassification (higher grade or greater volume)

Active surveillance has substantially reduced overtreatment of clinically insignificant prostate cancer, allowing men to preserve urinary and sexual function for years or decades while being closely monitored.

Digital Rectal Examination (DRE)

A DRE — the doctor inserting a gloved finger into the rectum to assess the prostate — can detect firmness, nodularity, or asymmetry. As a standalone screening test, DRE has poor sensitivity; most early prostate cancers are not palpable. But it adds information alongside PSA interpretation, particularly when PSA is in the 4–10 ng/mL range or when urinary symptoms are present.

After Treatment: Managing Long-Term Effects

The most common side effects of prostate cancer treatment — radical prostatectomy and radiation — include:

Erectile dysfunction — common after both surgery and radiation; more likely after nerve-involving surgery
Urinary incontinence — most common after radical prostatectomy; usually improves over 12 months with pelvic floor physiotherapy
Bowel changes — more common after radiation therapy

Awareness of these risks is a central part of informed decision-making before treatment. See Erectile Dysfunction — Causes, Cardiovascular Risk, and Treatment for management options after prostate cancer treatment.

Educational only; not a substitute for professional medical advice. Speak with your GP before starting or stopping any screening program.